NCT02437227View on ClinicalTrials.gov

A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 15, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

July 31, 2018

Conditions
MelanomaCancer
Interventions
DRUG

CCT3833

CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.

Trial Locations (2)

M20 4BX

Christie NHS Foundation Trust, Manchester

SM2 5PT

Royal Marsden NHS Foundation Trust, Sutton

All Listed Sponsors
collaborator

Institute of Cancer Research, United Kingdom

OTHER

collaborator

Wellcome Trust

OTHER

collaborator

Biomedical Research Centre for Cancer

UNKNOWN

lead

Royal Marsden NHS Foundation Trust

OTHER

NCT02437227 - A Phase I, First in Man Study to Evaluate the Safety and Tolerability of a panRAF Inhibitor (CCT3833/BAL3833)in Patients With Solid Tumours | Biotech Hunter | Biotech Hunter